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K Pistevou-Gombaki et al.
1,2 presented their positive experience from the palliative use of octreotide 
LAR in hepatic metastases from non-neuroendocrine tumors. On the other hand, there are several 
negative prospective studies of octreotide efﬁ  cacy in liver metastases and this policy is not accepted 
from al oncologists.
3,4 According to this literature controversy and in continuation to the above-mentioned 
studies, we would like to report our recent experience from the efﬁ  cient use of octreotide LAR in seven 
patients with symptomatic liver metastases from non-neuroendocrine tumors and in one female 
(80-years-old) with duodenal carcinoid.
Somatostatin has been shown to possess antimitotic activity against non-endocrine tumours, while 
octreotide, a somatostatin analogue, has shown considerable antitumor activity on animal models of 
various hepatic tumors. A possible antitumor mechanism of octreotide is a stimulatory effect on Kupffer 
cells, induction of apoptosis or other antiproliferative actions, which have been suggested but not 
proved.
5,6 Furthermore, somatostatin and its long-acting analogues are effective in symptom control in 
patients with advanced neuroendocrine gastrointestinal tumours.
7,8 Kouroumalis et al. reported a sig-
niﬁ  cant efﬁ  cacy of octreotide for the management of hepatocellular carcinoma.
9 Kapadia commenting 
on the improvement of quality of life after the administration of octreotide in patients with hepatocel-
lular carcinoma, reported that the possible mechanism of this, should be the diminishing of the effects 
of various humoral agents and/or cytokines released from the tumor.
10 However, the possible role of 
octreotide in palliative treatment of symptomatic liver metastases from non-neuroendocrine primary 
carcinomas remains controversial in the literature.
We report on seven patients, (3 females, 4 males), age: (63, 70, 71, 75, 72, 80, 81 years-old), with 
symptomatic liver metastases from different primary tumors -two from unknown primary origin, four 
from primary pancreatic carcinoma (two in the head and two in the tail of the pancreas) and one from 
duodenal carcinoid tumor-, who were palliatively treated by long acting octreotide IM (octreotide LAR) 
monthly, according to schema published previously.
2
In all patients multiple liver metastases in both liver lobes were demonstrated, either by abdominal 
echosonography, computed-tomography (CT), magnetic resonance imaging (MRI) or a combination of 
them. In four patients pancreatic tumor in the head (two patients) and in the tail (two patients) of the 
pancreas was demonstrated. In two patients no primary tumor was found despite meticulous examination 
in general hospital with chest X-ray, abdominal echosonography, computed-tomography (CT), magnetic 
resonance imaging (MRI), gastroscopy, colonoscopy and urological examination. In one female, 
80-years-old, a duodenal polypoid tumor, more than 5 cm, was found and histological examination was 
suitable of carcinoid tumor.
Clinical examination revealed slight enlarged liver in ﬁ  ve patients and severe liver mass in two 
patients. All patients complained for general symptoms attributed to hepatic metastases, including right 
upper abdominal pain, loss of appetite, malaise and weight loss. At ﬁ  rst instance all patients were 
palliatively treated by common analgesics and transdermal fentanyl, with slight improvement of the 402
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right upper abdominal pain. Eventually, when the 
liver pain deteriorated and produced severe 
morbidity, which could not respond to increase of 
the fentanyl doses, it was decided to treat all the 
patients with 20 mg long acting octreotide IM 
(octreotide LAR), once the ﬁ  rst day, octreotide SC 
0,5 mg X3/daily, days 2–14 and then 20mg long 
acting octreotide IM montly, as in our previous 
studies.
1,2
The follow-up was done with clinicolaboratory 
examination and abdominal ultrasonography 
before and at one-month intervals after the initia-
tion of octreotide therapy. The assessment of pain 
attributed to liver metastases was performed using 
the visual analogue scale (VAS) at baseline, at the 
time of octreotide IM injection and one week later 
(monthly). The improvement on palliative effect 
was also assessed every month using the analgesic 
intake scale (AIS) according to WHO (0 = no 
analgesics; 1 = NSAID; 2 = weak opioids; 
3 = morphine).
An interesting point of our study was that all 
patients who had some degree of pain improve-
ment, the local pain at the right upper abdomen 
relapsed when octreotide was temporarily stopped 
or at the end of every month just before the next 
injection of octreotide LAR and reduced again soon 
after the initiation of octreotide. One week after 
the administration of octreotide, the right upper 
abdominal pain was in general terms decreased. In 
fact, 2/7 (29%) patients reported excellent subjec-
tive improvement with more than 4 points decrease 
of VAS score. Moderate response (decrease of VAS 
by 2–4 points) was monitored in 2/7 (29%) patients, 
while only 3/7 (42%) patients showed slight relief 
of the pain (1 point decrease of VAS). During the 
ﬁ  rst month of treatment, the AIS was signiﬁ  cantly 
decreased from 2.8 ± 0.4 to 1.4  ± 0.5 (p =  0.023, 
Wilcoxon test). The data were analyzed using the 
Statistical Package for the Social Sciences (SPSS) 
for Windows (SPSS Inc., Chicago, 1993).
As far as the side effects are concerned octreo-
tide was generally well-tolerated. Slight hypergly-
cemia was reported in 4/7 patients (57%), treated 
by specific diet. Decompensation of diabetes 
mellitus was monitored in 1/7 patients (14%) 
treated by insulin injections. No other severe side 
effects due to octreotide-treatment were reported. 
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Figure 1. Time course of patients’ mean values AIS and VAS after octreotide administration.403
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Only one patient discontinued the 3rd session of 
the regimen due to gastrointestinal side effects 
(nausea, diarrhea). During follow-up, six months 
after the initiation of octreotide therapy, local pain 
improvement was still reported in 4/7 patients 
(57%). One patient died three months after the 
initiation of treatment due to generalized malignant 
disease. Concerning the current status of subjects 
entered the study, 6 out of 7 patients (85.7%) are 
still alive, six months after baseline of octreotide-
therapy. Totally 57% of patients showed some 
degree of pain relief, which could be attributed to 
octreotide use. The most important is that the values 
of VAS and AIS remained stable after the ﬁ  rst 
month of improvement, as it is shown in Figure 1.
The major disadvantage of octreotide use is 
hyperglycemia and decompensation of diabetes 
mellitus, which may be signiﬁ  cant but reversible.
9 
In the present, study although 71% of patients 
experienced hyperglycemia, this was not of clini-
cal signiﬁ  cance and none of the patients discon-
tinued the therapy due to this side effect.
In this study we did not have control group and 
the diversity of the primary tumors, with the tumor-
related morbidity, in relation to the placebo effect, 
which can result in improvement in cancer symp-
toms in as many as 40% of patients, made the 
evaluation of our results more difﬁ  cult. However, 
taking into account the unpredictable behavior of 
end-stage malignant disease, the role of multiple 
parameters involved and the necessity of indi-
vidualized policy in these debilitating patients, 
further studies are necessary in order to determine 
the subgroups of patients who might beneﬁ  t from 
octreotide.
We consider the use of octreotide potentially 
effective in clinical stabilization and a good alter-
native in palliative treatment of symptomatic liver 
metastases in patients with end stage malignant 
disease. The positive results of the present study 
encourage further randomized controlled trials of 
octreotide in the treatment of metastatic liver dis-
ease from different non-neuroendocrine tumors.
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